Prostate cancer is one of the most commonly seen malignancies. Radical prostatectomy - open, laparoscopic or robot-assisted - is considered the first-line treatment for intermediate and high-risk prostate cancer, along with radiotherapy, if the expected survival is greater than 10 years. Radical prostatectomy is also considered in case of low-risk patients alongside active follow-up. Today, robot-assisted radical prostatectomy is the most common surgical treatment for localised prostate cancer. It is associated with shorter hospitalisation times and lower transfusion requirements compared to open surgery. Satisfactory long-term biochemical recurrence-free survival and tumour-specific survival can be achieved with robot-assisted radical prostatectomy in the treatment of low-, intermediate- and highrisk prostate cancer. It has the advantage of rapid postoperative continence recovery and high potency recovery rates. The cost of the minimal invasive approach is higher compared to open radical prostatectomy, and the benefits of faster postoperative recovery should be further investigated to quantify cost-effectiveness. The robot-assisted approach has enabled a number of new surgical techniques and further rapid advances in this field are expected.